Pharmacology, Toxicology and Pharmaceutical Science
Infection
100%
Mycobacterium abscessus
57%
Antibiotics
51%
Delamanid
38%
Linezolid
38%
Amikacin
37%
Mycobacterium Tuberculosis
36%
Bedaquiline
32%
Cohort Study
28%
Lung Infection
28%
Bloodstream Infection
25%
Drug Development
24%
Clofazimine
24%
Pharmacokinetics
24%
Pretomanid
24%
Tuberculostatic Agent
24%
Ethambutol
24%
Clinical Trial
22%
Drug Resistant Tuberculosis
21%
Pharmacodynamics
19%
Antibiotic Therapy
19%
Human Study
19%
Mycobacterium marinum
19%
Rifamycin
19%
Predictive Modeling
19%
Tetracycline
19%
Effusion
19%
Monotherapy
19%
Imipenem
19%
Comorbidity
19%
Antimicrobial Resistance
19%
Diseases
19%
Aspergillus
19%
Active Metabolite
19%
Quinoline Derivative
19%
Hyperthermia
16%
Clarithromycin
15%
Streptococcus pneumonia
14%
Macrolide
12%
Lung Disease
12%
Infectious Agent
12%
Antimycobacterial Agent
12%
Prevalence
12%
Isoniazid Plus Pyrazinamide Plus Rifampicin
11%
Mouse Model
11%
Verapamil
11%
Thioridazine
11%
Cystic Fibrosis
9%
Crystal Violet
9%
Incubation Time
9%
Medicine and Dentistry
COVID-19
43%
Emergency Department
38%
Infection
28%
In Vitro
27%
Bloodstream Infection
25%
Retrospective Cohort Study
22%
Antibiotic Therapy
19%
Pseudallescheriasis
19%
Intensive Care Unit
19%
Aspergillus
19%
Lung Infection
19%
Virus Shedding
19%
Virus Infectivity
19%
Clinical Trial
19%
Public Health
19%
Mycobacterium Chimaera
19%
Confocal Microscopy
19%
Mycobacterium abscessus
19%
Drug Activity
19%
Comorbidity
19%
Odds Ratio
18%
Charlson Comorbidity Index
16%
Hyperthermia
16%
Pneumococcal Pneumonia
12%
Streptococcus pneumonia
12%
Blood Culture
12%
Vein Insufficiency
9%
Cellulitis
9%
Intermittent Pneumatic Compression
9%
Voriconazole
9%
Immunosuppressive Treatment
9%
Papule
9%
Edema
9%
Internal Medicine
9%
Thrombosis
9%
Diabetes
9%
Lower Leg
9%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Medicine
9%
Likert Scale
9%
Drug Resistant Tuberculosis
9%
Adverse Event
9%
Clinician
9%
Physical Disease by Body Function
9%
Patient Care
9%
Microbiological Examination
9%
Patient Monitoring
9%
Vital Sign
6%
Hypothermia
6%
Clofazimine
5%
Immunology and Microbiology
Drug Activity
38%
Mycobacterium abscessus
38%
Antibiotic Sensitivity
20%
COVID-19
19%
Comorbidity
19%
Virus Infectivity
19%
Biofilm
19%
Mycobacterium Chimaera
19%
Confocal Microscopy
19%
Viral Shedding
19%
Minimum Inhibitory Concentration
11%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Escherichia coli
9%
Staphylococcus Aureus
6%
Pseudomonas aeruginosa
6%
Morphotype
5%
